Genenta Progresses To Higher Dosing Cohort In Temferon Phase 1/2a Clinical Trial In Glioblastoma Multiforme
Genenta Science (NASDAQ:GNTA), a clinical-stage biotechnology company pioneering the development of hematopoietic stem progenitor cell immuno-gene therapy for cancer, announces that its ongoing trial of Temferon™
Genenta Data Presentation At AACR To Describe On-Target Biological Activity Of Temferon In Unmethylated Glioblastoma Multiforme
Genenta Science (NASDAQ:GNTA), a clinical-stage biotechnology company pioneering the development of hematopoietic stem progenitor cell immuno-gene therapy for cancer, will present clinical data from its Phase 1/2a
Stocks That Hit 52-Week Lows On Monday
On Monday morning, 49 companies achieved new lows for the year.
The Week Ahead In Biotech (Dec. 19-25): Amgen And Aquestive Regulatory Decisions Key Events Of Holiday-Shortened Week
Biotech stocks reversed course and advanced solidly in the week ending Dec. 17, as an increase in risk aversion pushed investors to buy into defensive stocks. The sector also drew strength from some positive stock-specific news.